Commitment and Talent Taking Targeted Therapeutics to Market
Our strength is in our team, including the investors and leaders who make up our Board:
Dr. Bolzon is a Managing Director with Versant Ventures. Dr. Bolzon brings more than thirteen years of global pharmaceutical industry experience to Versant’s biotech investment team. He specializes in early-stage biotech investing with a particular emphasis on new company start-ups.
Prior to joining Versant, Dr. Bolzon served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with F. Hoffmann-La Roche. Under his leadership, Roche established alliances with over 75 biotech companies worldwide and significantly strengthened its product pipeline. Previously, Dr. Bolzon held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs, and business development.
Dr. Vickers is the Chief Executive Officer of Northern Biologics, and a member of the Northern Biologics Board of Directors. Prior to joining Northern Biologics, Dr. Vickers served as Global Head of Research and Development and a member of the Executive Committee of Shire, a biotechnology company focused on the development of therapies for the treatment of rare and specialty conditions. Under Dr. Vickers’s leadership Shire’s pipeline had approximately 40 programs in clinical development in the areas of Genetic Disease, GI disease, Hematology, Immunology, Neuroscience, Ophthalmology and Oncology. Prior to Shire, Dr. Vickers held positions of increasing responsibility in Research and Development at Merck, Pfizer, Boehringer-Ingelheim and Resolvyx Pharmaceuticals. Dr. Vickers is also a member of the Board of Directors of Revance Therapeutics.
Dr. Vickers obtained his PhD in Biochemistry from the University of Toronto, which was followed by postdoctoral research in mechanisms of multidrug resistance in breast cancer at the National Cancer Institute in Bethesda, Maryland.
Dr. Wouters is an internationally recognized leader and cancer researcher. He became Executive Vice President of Science and Research at UHN in 2016 and prior to that served as the Interim Director of Research at the Princess Margaret Cancer Centre since 2014. He joined UHN in 2008 as Senior Scientist and Director of the Princess Margaret Hypoxia Program, and has held faculty appointments at the University of Toronto in the Department of Medical Biophysics and the Department of Radiation Oncology since that time.
Prior to joining UHN, Dr. Wouters was Professor and Head of Experimental Radiation Oncology at Maastricht University in the Netherlands. As EVP of Science and Research, Dr. Wouters is focused on creating an environment that incentivizes, facilitates, and rewards excellence in basic, translational, and clinical research across all elements of UHN.
Dr. Bisson is a Partner at Teralys Capital since 2011. Previously, Dr. Bisson headed the healthcare activities at iNovia Capital where he focused on building and investing in clinically meaningful opportunities in biopharmaceuticals, medical devices and related areas. Previously, he was associate principal at McKinsey & Company, a large international management consulting firm.His deep expertise in life sciences will contribute in executing Teralys’ strategy in this sector. Dr. Bisson is very active on the community and art front, he sits on numerous boards such as ProCure, Montreal InVivo and Montreal Biennale of Art. Cedric obtained an M.D. Degree from McGill University and a J.D. Degree from Université de Montréal.